Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. An insurer’s decision to delay reimbursement of drugs licensed ...
By Sneha S K April 16 (Reuters) - The U.S. Food and Drug Administration should be more transparent when granting accelerated ...
Post-approval research on existing medicines has improved patient outcomes and addressed unmet medical needs. In oncology, post-approval improvements to drugs reflect indications for additional cancer ...
Cancer drugs with higher clinical benefit in pivotal trials and without major safety concerns achieve full US Food and Drug Administration (FDA) approval more quickly. Drugs demonstrating substantial ...
These results suggest that “clinicians may be unaware of important clinical trial limitations identified by the FDA when making prescribing decisions." A majority of cancer drugs approved in the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results